Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

PRIMARY OBJECTIVES:

I. To evaluate a highly innovative project evaluating the feasibility of patient-centered home care PCHC as a new model of cancer care to reduce disparities and improve health related QoL (HRQoL) and patient reported-outcomes (PROs) in Black patients with advanced prostate cancer (CaP). (Phase I) II. Establish patient-centeredness by exploring patients' choice relative to the place of CaP treatment for certain aspects of therapy as well as end-of-life care.

III. Establish the acceptance and impact of PCHC on PROs and HRQoL in BM with advanced CaP.

OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups.

GROUP 1: Participants take part in a focus group or complete questionnaires and may take part in an interview on study.

GROUP 2: Participants complete questionnaires throughout the study.

Inclusion criteria

• GROUP 1 FOCUS GROUPS:

• Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer
• GROUP 1 SURVEYS:

• Are 18 years of age or older
• Have histologic evidence of prostate adenocarcinoma
• Are requiring, have required, or will require prostate cancer treatment
• Have an understanding of the protocol and its requirements
• Are willing to fill in a questionnaire and participate in a focused interview
• Are able and willing to sign an informed consent
• GROUP 1 INTERVIEWS:

• Enrollment in the survey phase of the protocol
• GROUP 2:

• Are 18 years of age or older
• Are Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
• Have histologic evidence of prostate adenocarcinoma
• Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel)
• Are receiving part of supportive care/symptom management and/or anti-cancer therapy in the home as part of Cancer Care Beyond Walls (CCBW)
• Have an understanding of the protocol and its requirements
• Are able and willing to sign informed consent

Exclusion criteria

• GROUP 1 FOCUS GROUPS:

• Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system
• GROUP 1 SURVEYS:

• Do not identify as Black men
• Have not been diagnosed with prostate cancer
• GROUP 1 INTERVIEWS:

• Not enrolled in the survey phase of the protocol
• GROUP 2:

• Do not identify as Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
• Have not been diagnosed with histologic evidence of prostate adenocarcinoma
• Are not requiring active standard anti-cancer therapy